熊去氧胆酸辅助治疗慢性乙型淤胆型肝炎的临床观察  

Clinical Observation of Ursodeoxycholic Acid in the Treatment of Chronic Cholestatic Viral Hepatitis B

作　　者：冯晓宁[1] 曾文权[1] 熊清芳[1] 

机构地区：[1]南京市第二医院肝病科,南京210003

出　　处：《中国药房》2014年第16期1471-1473,共3页China Pharmacy

摘　　要：目的:观察熊去氧胆酸辅助治疗慢性乙型淤胆型肝炎的临床疗效和安全性。方法:75例慢性乙型淤胆型肝炎患者以抛投硬币法随机分为对照组(40例)和观察组(35例)。两组患者均给予苦黄注射液、复方甘草酸苷等常规治疗后,对照组患者给予常规抗病毒治疗;观察组患者在对照组治疗的基础上给予熊去氧胆酸250 mg,口服,tid。两组患者疗程均为4周。观察两组患者的临床疗效,消化道症状消失时间和黄疸消失时间,比较治疗前后丙氨酸氨基转移酶(ALT)、总胆红素(TBIL)、碱性磷酸酶(ALP)、谷氨酰转肽酶(GGT)的变化及不良反应发生情况。结果:观察组患者总有效率显著高于对照组患者,消化道症状消失时间和黄疸消失时间均显著低于对照组患者,两组比较差异均有统计学意义(P<0.05)。治疗前两组患者ALT、TBIL、GGT、ALP比较差异无统计学意义(P>0.05);治疗后两组患者ALT、TBIL、GGT、ALP均显著低于同组治疗前,且除ALT外,观察组其他指标均显著低于对照组,差异有统计学意义(P<0.05)。两组患者治疗期间均未见明显不良反应发生。结论:熊去氧胆酸辅助治疗慢性乙型淤胆型肝炎疗效显著,安全性较好。OBJECTIVE： To observe the safety and clinical efficacy of ursodeoxycholic acid （UDCA） in the treatment of chron- ic cholestatic viral hepatitis B. METHODS： 75 patients with chronic cholestatic viral hepatitis B were randomly divided into control group （40 cases） and observation group （35 cases）. Two groups were given routine treatment of Kuhuang injection and Compound glycyrrhizin; control group was additionally given routine antiviral therapy; observation group was additionally given UDCA 250 mg, tid on the basis of control group. Treatment course of 2 groups lasted for 4 weeks. Clinical efficacy, the time of digestive tract symptoms disappearance and the time of jaundice disappearance were observed in 2 groups; the changes of ALT, TBIL, ALP, GGT and adverse drug reactions were compared between 2 groups before and after treatment. RESULTS： The total effective rate of observation group was significantly higher than that of control group. The time of digestive tract symptoms disappearance and the time of jaundice disappearance in observation group were significantly lower than in control group; there was statistical significance （P〈0.05）. There were no statistical significance in the difference of ALT, TBIL, GGT and ALP between 2 groups before treat-ment （P〉0.05）. After treatment, ALT, TBIL, GGT and ALP of 2 groups were significantly lower than before; those of observa-tion group were lower than those of control group, and there was statistical significance （P〈0.05）. ALT of 2 groups after treatment was significantly lower than before; there was statistical significance （P〈0.05）, but there was no statistical significance between 2 groups （P〉0.05）. No obvious ADR was found in 2 groups during treatment. CONCLUSIONS： UDCA is remarkably effective and safe treatment for chronic cholestatic viral hepatitis B.

关 键 词：慢性淤胆型肝炎 熊去氧胆酸 疗效 安全性 

分 类 号：R512.6[医药卫生—内科学]